PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Cash & equivalents declining -9.79% while AXSM's grows 6.12%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Below half of AXSM's 6.12%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
Below half of AXSM's 6.53%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-10.21%
Below half AXSM's 30.65%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
Below half of AXSM's 109.70%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Below half of AXSM's 6.62%. Michael Burry sees a potential red flag for stagnation or capital shortage.
3.20%
Less than half of AXSM's 20.85%. David Dodd sees a more disciplined AP approach or lower volume.
-75.32%
Similar yoy changes to AXSM's -100.00%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Below half of AXSM's -100.00%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Less than half of AXSM's -11.57%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Less than half of AXSM's 249.43%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Less than half of AXSM's 86.05%. David Dodd sees far fewer liability expansions relative to competitor.
7.69%
Above 1.5x AXSM's 0.19%. Michael Burry suspects heavy new equity expansion or dilution.
-2.53%
Below half AXSM's -10.11%. Michael Burry suspects major net losses or high dividends vs. competitor.
-4.62%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
Below half AXSM's -261.84%. Michael Burry sees potential underperformance in building shareholder capital.
-9.71%
Below half AXSM's -194.91%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Less than half of AXSM's 136.68%. David Dodd sees less overall debt expansion vs. competitor.
9.58%
Similar yoy changes to AXSM's 9.42%. Walter Schloss sees parallel net leverage strategies.